First Page | Document Content | |
---|---|---|
Date: 2010-10-19 13:01:20Lymphoma Histone deacetylase inhibitor Cutaneous T-cell lymphoma Romidepsin Vorinostat Histone deacetylase Merck & Co. Mesothelioma Targeted therapy Medicine Pharmacology Orphan drugs | Mesothelioma Articles - Merck & Co: Zolinza becomes first app...Document is deleted from original location. Download Document from Web Archive |